Agios Pharmaceuticals, Inc. (AGIO)
Health Care ยท Pharmaceutical Preparations
Agios Pharmaceuticals, Inc. (AGIO) is listed on Nasdaq, where its shares have traded since July 24, 2013. SentiSense covers Agios Pharmaceuticals, Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations. Brian Goff is its chief executive officer. The company reports 540 employees, and its corporate website is www.agios.com.
About Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 229 institutions reported holding AGIO, with 66.0 million shares worth $2.5 billion in aggregate. The largest reported holders were BlackRock, Vanguard and Farallon Capital Management. Of the 5 largest reported holders, all 5 added shares during the quarter.
More on AGIO
- AGIO sentiment: whether news and social coverage of Agios Pharmaceuticals, Inc. leans bullish or bearish, and the stories driving it.
- AGIO ownership: all 229 reporting institutions, plus insider and congressional trades.
- AGIO financials: revenue, net income, operating margin and free cash flow by quarter and year.
SentiSense also tracks daily options readings for Agios Pharmaceuticals, Inc.: IV rank, put/call percentile, 25-delta skew and open-interest walls.
Frequently asked questions
What does Agios Pharmaceuticals, Inc. do?
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology.
What sector is AGIO in?
SentiSense classifies Agios Pharmaceuticals, Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations.
Where does AGIO stock trade?
Agios Pharmaceuticals, Inc. (AGIO) is listed on Nasdaq, where its shares have traded since July 24, 2013.
Who is the CEO of Agios Pharmaceuticals, Inc.?
Brian Goff is the chief executive officer of Agios Pharmaceuticals, Inc..